Announcement on Result of Shareholding Reduction by Shareholder
Filed with SSE · · 3 pages · Chinese
Hinova Pharmaceuticals, Inc. on 6ix
Earlier from Hinova Pharmaceuticals
- 2025 Semi-annual Report
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 5%
- Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1%
- Announcement on Voluntary Disclosure of Approval of New Drug Marketing Application for Deutenzalutamide Soft Capsules
- Announcement on Convening the Q1 2025 Performance Briefing
Later from Hinova Pharmaceuticals
- Announcement on Attending Collective Performance Briefing for Innovative Drug Industry on Semi-annual SSE STAR Market 2025
- Announcement on Listing and Circulation of Partial Restricted Shares in Initial Public Offering
- Announcement on Resignation of Independent Director and By-election of Independent Director, and Adjustment of Members of Special Committees of the Board of Directors
- Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
- Announcement on Voluntary Disclosure of Completion of Inclusion of the First Batch of Participants in Phase II Clinical Trial of the Drug HP515 for Treating Metabolic-Associated Steatohepatitis (MASH)
Follow Hinova Pharmaceuticals into a list and get an email when it puts out news.
Follow Hinova Pharmaceuticals